The Latest Cardiac and Vascular News
– JK07 Advancing into Phase 2 Clinical Trial in Heart Failure with Reduced Ejection Fraction (HFrEF); Topline Phase 1b Results Expected in 1H 2023 – –Fourth Cohort Enrolling in Phase 1/2 Study Evaluating JK08 Monotherapy in Advanced Solid Tumors; Favorable Pharmacodynamic Activities Observed Across Cohorts – GAITHERSBURG, Md.–(BUSINESS WIRE)–Salubris Biotherapeutics, Inc. (SalubrisBio), a clinical-stage biotechnology […]
– Completed Second Cohort Showed an Average 30% Relative Increase in Ejection Fraction (EF) at 90 Days Following a Single Administration of JK07 – – Cohort 3 Sentinel Subject Demonstrated a >70% Relative EF Increase at Day 30 – – Company also Announces the First CTA Approval for JK08, the First […]
– Lead Clinical Candidate, JK07, Demonstrates Favorable Safety and Further Promising Activity in Cohort 2 of Phase 1b Heart Failure with Reduced Ejection Fraction Study; Enrollment in Cohort 3 Now Ongoing – – Clinical Trial Application Submitted in Europe for Lead Oncology Program JK08, the first CTLA-4/IL-15 Antibody Fusion Protein, […]
